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Abstract
The US Food and Drug Administration (FDA) developed a draft guidance for drug de-
velopment in amyotrophic lateral sclerosis (ALS) that was issued in February 2018. The FDA
draft guidance considered the recommendations developed by the ALS community that in-
corporated the views of a large group of clinical investigators, industry representatives, advocacy
groups, patients, and caregivers. This external input from the ALS community reviewed the
current state of clinical research in ALS, made suggestions over a wide range of drug de-
velopment topics, and served as an educational tool to provide the agency with additional
inputs about ALS, the state of the science, and the community’s views on key topics. In parallel
to this effort, there was an independent effort to revise and update the ALS Clinical Trial
Guidelines. We discuss the areas of agreement of these 3 documents and the areas that provide
opportunities to improve the efficiency of drug development in ALS. It is likely that further
research into biomarkers, efficacy endpoints, and predictive algorithms will provide greater
alignment among community stakeholders and increase clarity on drug development efforts
going forward. Continued patient engagement and inclusion of patient experience data in every
aspect of the drug development process will further facilitate the approval of new treatments.
Introduction
Over the past several years, the US Food and Drug Administration (FDA) has increased efforts to
integrate the patient voice into the drug development process. As part of this commitment, Patient-
FocusedDrugDevelopment is an FDA initiative intended to bring patient perspectives at all stages of
investigational drug development and the regulatory review process.1 This initiative also aims to
develop new assessment tools and clinical trial endpoints and to provide a framework to incorporate
patient and caregivers views regarding the unmet need, what is clinically meaningful, and risk. The
FDA has accepted externally developed guidance documents to obtain input from the commu-
nity regarding disease-specific drug development. Although these documents are ultimately gener-
ated by the FDA, community and professional input is sought by the agency. With respect to
amyotrophic lateral sclerosis (ALS), a recently completed a draft guidance for industry (Community
Guidance; data available from Dryad, doi.org/10.5061/dryad.43qc486) incorporated the views of
a large group of clinical investigators, industry representatives, advocacy groups, patients, and care-
givers. The Community Guidance reviews the current state of clinical research in ALS and makes
suggestions over a wide range of drug development topics. The Community Guidance included
content that goes far beyond what typically is found in an FDA draft drug development guidance
document in order to serve as an educational tool and to provide the agency with additional inputs
about ALS, the state of the science, and the community’s views on key topics.
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This community guidance was submitted to the FDA, which
in turn developed an FDA draft drug development guidance
document for public comments that responded in part to the
community guidance.2 Although nonbinding, FDA guidance
documents can be highly influential. Developed for industry,
FDA staff, and other stakeholders, the document is intended
to provide clarity in key areas: content and evaluation of
applications for products, manufacturing standards, testing of
regulated products, and inspection and enforcement.
Independent of but parallel to the guidance development
process, ALS clinician investigators initiated the update and
revision of the previously published ALS Clinical Trial
Guidelines.3 This revision, published in Neurology®,4 was
created with a formal consensus process that is not de-
scribed here. The guidelines were conceived to guide in-
dustry and academic investigators in best practices for
clinical trials.
The purpose of this discussion is to highlight the points of
agreement among the 3 documents—the community guid-
ance, the draft FDA guidance, and the Clinical Trial
Guidelines—and to show specific points of nonalignment.
Guidance development/methods
Community engagement and
development process
At a public hearing in 2013, the FDA encouraged the ALS
community to develop a draft guidance to inform the de-
velopment of an FDA-issued guidance document for drug
development in ALS. Starting in 2015, ALS clinicians and
researchers, patients, caregivers, advocacy group representa-
tives, pharma, and federal government representatives from
the NIH and Centers for Disease Control and Prevention
began the process of drafting the community guidance. The
project was governed by a steering committee made up of
subject matter experts and representatives of key constitu-
encies within the ALS community.
Seven working groups (benefit-risk, public policy, diagnosis,
natural history, clinical trial design and outcome measures,
frontotemporal dementia and ALS, and biomarkers) were
established to oversee and develop specific chapters of the
guidance. Each working group had representation from a va-
riety of perspectives and included at least 1 person with ALS.
As content was developed, it was periodically reviewed by the
steering committee. The preliminary guidance document,
which was shared with the greater ALS community in May
2016 for input during a 30-day public comment period, was
revised and submitted to the FDA in September 2016 and
docketed by the agency in November 2017.
Importantly, a Patient and Caregiver Advisory Committee
(PCAC) was established to work closely with the steering
committee and working groups to provide patient per-
spectives. The PCAC provided comments and suggestions on
every aspect of the guidance development. Participants on the
PCAC included nearly 40 people with ALS, caregivers, family
members, and individuals from other ALS organizations. The
final Community Guidance was posted on the Public Docket
in November 2017.
Community Guidance
The draft guidance developed by the ALS community is
a detailed document that reviews the state of knowledge re-
garding pathophysiology, genetics, and disease course in ALS;
however, specific recommendations are embedded within the
document as Proposed Guidances, which were intended as
specific suggestions to which an FDA response was requested.
Briefly, the major topics included the following:
1. Patients with ALS in general are willing to accept more
risks than other patient groups with regard to testing new
therapies and would regard nontraditional endpoints as
potentially compelling.
2. New endpoints, including respiratory measures, muscle
strength, and disease progression markers yet to be
validated, should be considered as phase 3 clinical trial
endpoints. Specifically, survival was viewed not to be an
ideal clinical trial endpoint because its use mandates
large, long duration trials.
3. The development of surrogate endpoints or intermediate
clinical endpoints is encouraged; to the extent that they
reliably predict important clinical outcomes, these end-
points should be acceptable to support accelerated approval.
4. While the design of predictive algorithms remains an active
area of research, late-phase trials should still involve the use
of a concurrent randomized control group.
5. Inclusion criteria should be as broad as possible, both to
increase access to trials and to maximize generalizability
of results.
6. Expanded access programs should be considered,
especially for patients not eligible for most clinical trials.
These programs should be implemented earlier in the
development process than has traditionally been the case.
7. Genetic stratification should occur in all trials because
differential efficacy based on genetics may occur even
with agents not specifically aimed to target a single gene.
This should occur in the context of a robust genetic
counseling program.
Glossary
ALS = amyotrophic lateral sclerosis; FDA = Food and Drug Administration; PCAC = Patient and Caregiver Advisory
Committee.
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FDA draft drug development guidance
The FDA draft guidance for drug development, issued in
February 2018, considered the ALS community recom-
mendations above. It is important to recognize that the FDA
guidance is not a legally enforceable document. Instead, the
draft drug development guidance is intended to describe the
agency’s current thinking on a topic and should be viewed as
recommendations. This document highlighted the following
considerations:
1. The FDA specifically recognized that the progressive and
ultimately fatal nature of ALS may affect considerations
of risk and tolerance of new medications, consistent with
the Community Guidance.
2. There is heterogeneity among the ALS patient popula-
tion. If an investigational drug is expected to be generally
effective in ALS, then the study should include a broader
ALS population. The FDA supported the use of targeted
subgroups as long as there was a scientific justification
such as a drug targeting a specific gene or disease
mechanism not expected to be present in all patients.
3. Measures of efficacy should always include mortality for
considerations of both safety and efficacy. A mortality
endpoint should always include the need for permanent
assisted ventilation. Mortality is a potentially approvable
endpoint, as are functional scales such as the Amyo-
trophic Lateral Sclerosis Functional Rating Scale–revised
or the Appel Rating Scale. No other existing measures are
mentioned, although the guidance does not rule out
measures to be developed in the future.
4. The FDA recognized the typically rapid progression of
disease in patients with ALS and suggested that study
duration should be “practicable,” even if this results in only
a modest beneficial effect. With regard to surrogate
endpoints, the lack of credibility of current potential
surrogates is mentioned such that, while opportunities for
the use of surrogate endpoints to support accelerated
approvalmay exist in the future, this is not currently the case.
5. Although the use of predictive algorithms is not
specifically mentioned, the FDA document encouraged
the use of all methods that effectively ensure the
equivalence of treatment and control groups. Any use
of historical controls, whether in the context of a pre-
dictive algorithm, was strongly discouraged.
Alignments and divergences of the
community guidance, FDA draft drug
development guidance, and the ALS
Clinical Trial Guidelines
Alignment
Risk-benefit considerations
The FDA draft drug development guidance acknowledges
that when making regulatory decisions about drugs to treat
ALS, the FDA will consider patient tolerance for risk and the
serious life-threatening nature of the condition. This aligns
with the Community Guidance, which specifically discusses
risk-benefit assessment and the need for appropriate balance
between the increased tolerance of people with ALS for drug
development risk, given the prognosis, and the continued
protection of people with ALS from their potential
exploitation.
Heterogeneity (clinical trial population)
All of the documents generally agree that the ALS population
is heterogeneous. However, the Community Guidance details
specific issues related to disease heterogeneity and specific
subpopulations of patients with ALS.
The FDA draft drug development guidance also discusses trial
eligibility criteria as they relate to subpopulations and affirms
that drug development can be targeted to an identified ALS
subgroup or to ALS variants when scientifically justified.
However, if an investigational drug is expected to be generally
effective, then a broader patient population needs to be
studied. Of note, however, the approval of edaravone to treat
patients with ALS applied to all patients with ALS despite the
use of stringent eligibility criteria in the clinical trial.4
Efficacy endpoints
All of the documents agree that favorable effects on function
and survival can establish efficacy in patients. Although the
FDA draft drug development guidance generally states that
efficacy should be established by demonstration of a clinically
meaningful effect on symptom or function or a favorable effect
on survival, there is emphasis on survival as an essential
endpoint, differentiating it from the other documents. The
FDA draft drug development guidance asserts that functional
endpoints can be confounded by missing data and death.
Given this vulnerability of functional endpoints, the FDA
guidance recommends using an analysis method that com-
bines survival and function into a single overall measure such
as the joint rank test.5 The ALS Clinical Trial Guidelines and
the Community Guidance also view this combined endpoint
for clinical trials as acceptable.
The FDA draft drug development guidance also favorably
discusses time to event endpoints, for which the event repre-
sents clinically meaningful worsening of disease. This also
allows the possibility of transitioning patients to open-label
treatment once a predetermined event has occurred. In addi-
tion, the Community Guidance highlights time to event end-
points as a means to shorten trials if sufficient events occur.
Both the ALS Clinical Trial Guidelines and the Community
Guidance suggest a spectrum of functional endpoints that
might support approval, but the FDA draft drug development
guidance does not mention specific functional endpoints.
Instead, it states that new endpoints that demonstrate
meaningful functional changes may be considered as potential
phase 3 endpoints.
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Pharmacokinetics/pharmacodynamics
All 3 documents are similar in their discussions of nonclinical
and clinical pharmacology studies. Both the FDA draft drug
development guidance and the Community Guidance note
that chronic toxicology studies can delay development time-
lines and prevent open-label extension protocols.
The FDA draft drug development guidance notes that it may
be appropriate to initiate clinical trials on the basis of less-
than-usual nonclinical testing if scientifically justified for se-
rious and life-threatening diseases for which treatments are
not available or are inadequate. It also discusses that the du-
ration of dosing in humans may exceed that of the nonclinical
studies if justified by the available nonclinical and clinical data.
In addition, the FDA draft development guidance suggests
that carcinogenicity studies can generally be conducted after
approval for drugs intended to treat ALS, given the unmet
need for effective therapies. Other human clinical pharma-
cology studies such as renal or hepatic studies may be waived
if the patient population and the metabolic pathways of the
drug suggest a low likelihood of clinically meaningful phar-
macokinetic and pharmacodynamic effects.
Divergence
Study design
The FDA draft drug development guidance strongly recom-
mends that sponsors conduct randomized, placebo (or stan-
dard of care)-controlled double-blind studies because these
studies are the most efficient way to demonstrate efficacy. The
ALS Clinical Trial Guidelines and the Community Guidance
also emphasize that randomized controlled trials remain the
most robust way to demonstrate efficacy. However, these 2
documents emphasize the need for flexibility and innovation
in clinical trial design, including unequal treatment groups
and multiple drug comparisons. Overall, each of the docu-
ments highlights the potential utility of an adaptive clinical
trial design.
The FDA draft drug development guidance strongly dis-
courages the use of historical controls. Both the ALS Clinical
Trial Guidelines and the Community Guidance are less pre-
scriptive and suggest the possibility that well-matched his-
torical controls may provide useful comparator information
for middle-stage trials.
Predictive algorithms are not discussed in the FDA draft drug
development guidance but are another avenue by which his-
torical controls may be used. The ALS Clinical Trial Guide-
lines emphasize the potential utility of technology assisted
measurements as exploratory endpoints. The Community
Guidance notes that although the Center for Devices and
Radiological Health has qualification requirements for
technology-assisted measurements,6 the Center for Drug
Evaluation and Research has no such guideline. The Com-
munity Guidance also suggests that predictive algorithms
could be explored in the middle phase of trials and that similar
algorithms could be used to efficiently stratify patients for
clinical trials.
Endpoints
The FDA draft drug development guidance is more stringent
regarding efficacy endpoints than the other documents. As
noted above, both functional and survival endpoints are en-
dorsed with an emphasis on survival. A variety of secondary
endpoints are proposed to support survival or functional
endpoints.
The Community Guidance also endorses survival as suffi-
cient to support approval of an investigational drug for ALS.
However, other endpoints are felt to be more appropriate
because a survival endpoint would require long-duration
studies with large sample sizes. Trial duration and sample
size are major drivers of cost and clinical trial efficiency. The
ALS Clinical Trial Guidelines also suggest a variety of
nonsurvival endpoints to support approval and note that
neither survival nor the more commonly used rating scales
are sensitive endpoints in phase 2 studies. For these reasons,
the ALS Clinical Trial Guidelines and the Community
Guidance support the continued study and potential use of
a variety of measures assessing motor strength and func-
tional capacity in future middle- and late-phase clinical
trials.
The FDA draft drug development guidance discusses
quantitative endpoints for strength and respiration but
suggests that results can be affected by patient motivation,
effort, and expectation bias. This is in direct conflict with
the other documents, which express the strong view that
quantitative measures of muscle strength and pulmonary
function should be considered adequate to demonstrate
efficacy in future clinical trials because they are well
characterized and reproducible across many prior ALS
studies.
Reassuringly, the FDA draft drug development guidance
states that the FDA will consider proposals for the use of new
outcomes measures that are capable of measuring clinically
meaningful effects in patients.
Accelerated approval
The FDA draft drug development guidance differs from the
other documents in its view of the accelerated approval
process and suggests that the rapid progression of disease in
ALS renders accelerated approval unnecessary. The lack
of credible surrogate endpoints is also cited as limiting
accelerated approval. The Community Guidance and the
ALS Clinical Trial Guidelines acknowledge the lack of clear
surrogate markers but view such development as critical to
more efficient trials. Thus, although the documents differ in
tone, recommendations for the use of surrogate markers do
not diverge.
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Omission
The FDA draft drug development guidance makes no mention
of issues specific to ALS when conducting studies that involve
cell therapy or gene therapy. Specifically, there is no discussion
of study populations, use of control arms, or considerations
regarding safety and efficacy despite several investigational stem
cell– and gene-directed studies entering early-phase clinical
development in patients with ALS. In addition, the FDA draft
drug development guidance does not discuss considerations
regarding studies targeting a specific gene mutation in familial
ALS that would involve small numbers of patients and may
preclude standard trial designs. The topic is discussed in detail
in both the Community Guidance and the ALS Clinical Trial
Guidelines. However, there is a general guidance for industry
regarding cell and gene therapy provided by the FDA that
discusses this topic more broadly.7
Discussion
Overall, there are key points to which all of the documents align.
One major area addressed in the FDA draft drug development
guidance is the flexibility in nonclinical and early clinical phar-
macology studies. This flexibility in nonclinical studies such as
clinical pharmacology, chronic toxicology, and carcinogenicity
studies will provide more efficiency of moving investigational
drugs forward to human clinical trials. However, once an in-
vestigational drug is ready for phase 3 testing, the FDA draft
drug development guidance does not suggest outcome meas-
ures other than those used for the past several decades. Using
these same endpoints will continue to make ALS therapeutic
development slow and inefficient. However, it is encouraging
that the FDA is willing to consider novel functional outcomes.
The tasks of validating and demonstrating clinical meaningful-
ness of any newmeasure will be critical for the ALS community.
Although the waivers for some clinical pharmacology studies
such as hepatic or renal studies may reduce a portion of
clinical development time, the effect on overall efficiency will
be small. The FDA draft drug development guidance
acknowledges that long duration and large sample sizes in
phase 3 studies impose burdens on the conduct of clinical
trials and mentions that some existing outcomemeasures may
be considered sufficient for approval.
Several major gaps need to be addressed to facilitate more
efficient clinical trials in patients with ALS. Continued work is
necessary to develop surrogate markers of clinical benefit that
satisfies the requirement of the regulatory criteria. It will be
a challenge to conduct a clinical trial of an investigational drug
that can achieve accelerated approval without these credible
surrogate markers. The Community Guidance and the ALS
Clinical Trial Guidelines highlight various potential surrogate
markers, but further work is needed to establish credibility of
potential surrogate endpoints that is reasonably likely to predict
clinical benefit to serve as a basis for accelerated approval.
All of the documents also agree that randomized, placebo-
controlled, double-blind studies are the most robust to
demonstrate efficacy of investigational drugs. However, pre-
dictive algorithms using historical data may be scientifically
valid both for improved stratification and to generate com-
parators in earlier-phase trials. Further work is needed to
identify the ideal role of historical controls and predictive
algorithms in the course of clinical drug development.
Finally, several outcome measures highlighted in the
Community Guidance and the ALS Clinical Trial Guide-
lines assess quantitative muscle strength or pulmonary
function. The FDA draft drug development guidance does
not address these endpoints and suggests that these meas-
ures are not sufficient to support approval of an agent. It is
therefore left to investigators to perform studies to demonstrate
the relationship of these endpoints to outcomes that are con-
sidered to be clinically relevant by regulators, investigators, and
the patient community.
Conclusion
The development of a Community Guidance in parallel with
the updated ALS Clinical Trial Guidelines brought together
a diverse set of stakeholders in the ALS community and en-
abled the sharing of the most recent science and open dialog
and debate in many of the challenging areas. While there were
many areas of agreement, there is lack of consensus on a va-
riety of issues that could improve the efficiency of clinical
trials. It is likely that further research into biomarkers, end-
points, and predictive algorithms will provide greater align-
ment among community stakeholders and increase clarity in
drug development efforts going forward. Continued patient
engagement and inclusion of patient experience data in every
aspect of the drug development process will further facilitate
the approval of new treatments.
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